發(fā)布時(shí)間:
2022
-
11
-
24
點(diǎn)擊次數(shù):
0
所屬職位：
總經(jīng)理
所屬公司：
山東新華制藥股份有限公司
個(gè)人簡介：
杜德平，男，1969年8月生，山東高密人，漢族，中共黨員，研究生學(xué)歷，高級工程師，執(zhí)業(yè)藥師。1987年9月至1991年7月在中國海洋大學(xué)學(xué)習(xí)，1991年7月在山東新華制藥股份有限公司參加工作，歷任車間產(chǎn)品技術(shù)員、技術(shù)處主管工程師、車間副主任、車間主任。2008年5至2008年12月，任山東新華制藥股份有限公司總經(jīng)理助理，2008年12月至2010年8月任副總經(jīng)理，2010年8月至今任總經(jīng)理。是山東省藥學(xué)會(huì)專業(yè)委員會(huì)委員、淄博市企業(yè)聯(lián)合會(huì)、企業(yè)家協(xié)會(huì)副主席，先后榮獲淄博市第六屆青年科技獎(jiǎng)、振興淄博五一勞動(dòng)獎(jiǎng)?wù)隆⒆筒┦锌茖W(xué)技術(shù)獎(jiǎng)二等獎(jiǎng)、2020影響淄博年度創(chuàng)新人物、山東省科學(xué)技術(shù)獎(jiǎng)二等獎(jiǎng)、山東省技術(shù)市場科技金橋獎(jiǎng)、中國石油和化學(xué)聯(lián)合會(huì)科技進(jìn)步獎(jiǎng)二等獎(jiǎng)等榮譽(yù)。山東新華制藥股份有限公司1943年誕生于膠東抗日根據(jù)地，1948年遷至張店。經(jīng)過70多年的發(fā)展，公司已成為H股、A股上市公司，全球重要的解熱鎮(zhèn)痛藥生產(chǎn)和出口基地，國內(nèi)重要的心腦血管類、抗感染類、中樞神經(jīng)類、生物藥物等生產(chǎn)企業(yè)，擁有化學(xué)原料藥、醫(yī)藥制劑、醫(yī)藥中間體三大支柱產(chǎn)業(yè)，五大產(chǎn)業(yè)園區(qū)，總資產(chǎn)60億元，職工6400余名?；瘜W(xué)原料藥年生產(chǎn)能力4萬噸，醫(yī)藥中間體50萬噸，片劑80億片，小容量注射劑8億支、大容量注射劑1000萬瓶、膠囊15億粒。主導(dǎo)原料藥布洛芬、阿司匹林、咖啡因等列模規(guī)均居全球前列，擁有吡哌酸等8個(gè)國內(nèi)獨(dú)家原料藥品種。Mr. Du Deping, male, born in August 1969, from Gaomi, Shandong, Han nationality, member of the Communist Party of China,postgraduate qualifications, senior engineer, licensed pharmacist. From September 1987 to July 1991, he studied at Ocean University of China, and worked in Shandong Xinhua Pharmaceutical Co., Ltd. In July 1991. He has served as workshop product technician, technical department supervisor engineer, workshop deputy director, and workshop director. From May 2008 to December 2008, he served as assistant to the general manager of Shandong Xinhua Pharmaceutical Co., Ltd., deputy general manager from December 2008 to August 2010, and general manager since August 2010. Member of the Professional Committee of Shandong Pharmaceutical Association, Vice Chairman of Zibo Enterprise Confederation, Entrepreneur Association, the Sixth Zibo Youth Science and Technology Award, the Revitalization of Zibo “May 1” Labor Medal, the Second Prize of Zibo Science and Technology Award, and the 2020 Impact Innovative Person of the Year in Zibo, the second prize of Shandong Science and Technology Award, the Golden Bridge Award of Shandong Technology Market Science and Technology, the second prize of Science and Technology Progress Award of China Petroleum and Chemical Federation and other honors.Shandong Xinhua Pharmaceutical Co., Ltd. was established in the Jiaodong Anti-Japanese Base in 1943 and moved to Zhangdian in 1948. After more than 70 years of development, she has become a H-share and A-share listed company, and an important global production and export base for antipyretic and analgesics. An important domestic manufacturer of cardiovascular and cerebrovascular, anti-infective, central nervous, and biological drugs. She has three pillar industries: chemical raw materials, pharmaceutical preparations, and pharmaceutical intermediates, five major industrial parks, with total assets of 6 billion RMB, and more than 6,400 employees. The annual production capacity of API is 40,000 tons, 500,000 tons of pharmaceutical intermediates, 8 billion tablets, 800 million small-capacity injections, 10 million bottles of large-capacity injections and 1.5 billion capsules. Leading API such as Ibuprofen, aspirin, and caffeine all rank among the top level in the world, and she has 8 domestic exclu